HOME Top Market Reports Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021

Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021

By: marketsandmarkets.com
Publishing Date: August 2016
Report Code: BT 3113

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global vaccines market is expected to reach 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3%. The global market is broadly classified into technology, type, disease indication, end-users, and regions.

On the basis of technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. The conjugate vaccines segment is expected to account for the largest share of the global market in 2016. Increasing government support for vaccine development and rising company investments will drive the growth of this market segment.

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent vaccines segment is expected to account for the largest share of this market. The large share of the market is attributed to rising prevalence of diseases and increasing government and non-government initiatives for vaccine R&D activities.

Disease indications, included in the vaccines market are pneumococcal disease, influenza, diphtheria, tetanus, and pertussis (DTP), hepatitis, rotavirus, varicella, meningococcal disease, polio, measles, mumps, and rubella (MMR), human papilloma virus (HPV) infection, and others. The pneumococcal disease segment is expected to account for the largest share of the global market in 2016. High incidence of pneumococcal infections and the need for immunizations to prevent the disease increases the market growth of this segment.

End-users, included in the vaccines market are paediatrics and adults. The paediatrics segment is expected to account for the largest share of the global market in 2016. Rising number of awareness programs to promote vaccination have resulted in the increasing use of vaccines for paediatrics.

Geographically, the vaccines market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by government initiatives for immunization against diseases such as influenza and HPV in the North American countries.

The major players in the vaccines market are Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), and Serum Institute of India Pvt. Ltd. (India).

Target Audience for this Report:

  • Vaccine Manufacturers
  • Clinical Laboratories
  • Vaccine Associations
  • Vaccine Research Institutes
  • Research and Consulting Firms
  • Vaccine Product Distributors
  • Group Purchasing Organizations (GPOs)
  • Vaccine Raw Material Suppliers
  • Immunization Centers
  • Vaccine Development Institutes and Organizations
  • Hospitals and Laboratories
  • Biotechnology and Biopharmaceutical Companies

Value Addition for the Buyer:

This report aims to provide insights into the global vaccines market. It provides valuable information on the technology, type, disease indication, and end-users, in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

The above-mentioned information would benefit the buyer by helping them understand the market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize the growth opportunities.

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report:

This report categorizes the vaccines market into the following segments:

Vaccines Market, by Product

  • Conjugate vaccines
  • Live Attenuated vaccines
  • Inactivated and Subunit Vaccines
  • Toxoid vaccines
  • Recombinant vaccines

Vaccines Market, By Type  

  • Monovalent vaccines
  • Multivalent vaccines

Vaccines Market, By Disease Indication

  • Pneumococcal Disease
  • Influenza
  • DTP
  • Hepatitis
  • Rotavirus
  • Varicella
  • Meningococcal Disease
  • Polio
  • MMR
  • Human Papilloma Virus (HPV) infection
  • Others

Vaccines Market, By End Users

  • Pediatrics
  • Adults

Vaccines Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia
    • Japan
    • China
    • India
    • Rest of Asia (RoA)
  • Rest of the World (RoW)

Customization Options:

  • Company Information: Detailed company profiles of five or more market players
  • Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Table of Contents

1 Introduction (Page No. - 16)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Market Segmentation
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Limitation
    1.5 Market Stakeholders

2 Research Methodology (Page No. - 19)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
    2.3 Market Share Estimation
    2.4 Key Data From Secondary Sources
    2.5 Key Data From Primary Sources
    2.6 Key Industry Insights
    2.7 Assumptions for the Study

3 Executive Summary (Page No. - 27)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook
    3.4 Conclusion

4 Premium Insights (Page No. - 31)
    4.1 Global Vaccines Market
    4.2 Vaccines Market, By Type
    4.3 Geographic Analysis: Market, By End User
    4.4 Geographic Analysis: Market, By Technology
    4.5 Geographical Snapshot of the Market
    4.6 Lifecycle Analysis, By Region, 2016

5 Market Overview (Page No. - 36)
    5.1 Introduction
    5.2 Market Segmentation
    5.3 Market Dynamics
           5.3.1 Drivers
                     5.3.1.1 High Prevalence of Diseases
                     5.3.1.2 Rising Government and Non-Government Funding for Vaccine Development
                     5.3.1.3 Increasing Investments By Companies
                     5.3.1.4 Increasing Government Focus on Immunization Programs
           5.3.2 Restraints
                     5.3.2.1 Huge Capital Investments
                     5.3.2.2 Stringent Regulations
           5.3.3 Opportunities
                     5.3.3.1 High Growth Prospects in Emerging Markets
                     5.3.3.2 Therapeutic Vaccines
                     5.3.3.3 Adjuvant Vaccines
           5.3.4 Challenges
                     5.3.4.1 Inadequate Access to Vaccines
                     5.3.4.2 Vaccine Pricing
           5.3.5 Burning Issues
                     5.3.5.1 Vaccine Failure
    5.4 Investment Analysis
    5.5 Regulatory Landscape
           5.5.1 North America
           5.5.2 Europe
           5.5.3 Asia
           5.5.4 RoW
    5.6 Patent Analysis
    5.7 Key Pipeline Products

6 Vaccines Market, By Technology (Page No. - 57)
    6.1 Introduction
    6.2 Conjugate Vaccines
    6.3 Inactivated and Subunit Vaccines
    6.4 Live Attenuated Vaccines
    6.5 Toxoid Vaccines
    6.6 Recombinant Vaccines

7 Vaccines Market, By Type (Page No. - 66)
    7.1 Introduction
    7.2 Monovalent Vaccines
    7.3 Multivalent Vaccines

8 Vaccines Market, By Disease Indication (Page No. - 71)
    8.1 Introduction
    8.2 Pneumococcal Disease
    8.3 DTP
    8.4 Influenza
    8.5 Human Papilloma Virus
    8.6 Meningococcal Disease
    8.7 Polio
    8.8 Rotavirus
    8.9 Hepatitis
    8.10 MMR
    8.11 Varicella
    8.12 Others

9 Vaccines Market, By End User (Page No. - 87)
    9.1 Introduction
    9.2 Pediatrics
    9.3 Adults

10 Vaccines Market, By Region (Page No. - 92)
     10.1 Introduction
     10.2 North America
               10.2.1 U.S.
               10.2.2 Canada
     10.3 Europe
               10.3.1 Germany
               10.3.2 U.K.
               10.3.3 France
               10.3.4 Italy
               10.3.5 Spain
               10.3.6 Rest of Europe (RoE)
     10.4 Asia
               10.4.1 Japan
               10.4.2 China
               10.4.3 India
               10.4.4 Rest of Asia (RoA)
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 120)
     11.1 Overview
     11.2 Market Share Analysis
     11.3 Competitive Situation and Trends
               11.3.1 Agreements, Collaborations, and Partnerships
               11.3.2 Regulatory Approvals
               11.3.3 Acquisitions
               11.3.4 Expansions
               11.3.5 Other Developments

12 Company Profiles (Page No. - 127)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     12.1 Introduction
     12.2 Pfizer, Inc.
     12.3 Glaxosmithkline, PLC.
     12.4 Merck & Co., Inc.
     12.5 Sanofi Pasteur
     12.6 CSL Limited
     12.7 Emergent Biosolutions, Inc.
     12.8 Johnson & Johnson
     12.9 Medimmune, LLC. (A Subsidiary of Astrazeneca)
     12.10 Astellas Pharma Inc.
     12.11 Serum Institute of India

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 151)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports


List of Tables (89 Tables)

Table 1 Incidence of Diseases, 2014-2015
Table 2 Nih Funding for Vaccine Research, 2012-2016 (USD Million)
Table 3 High Prevalence of Diseases to Boost the Vaccines Market
Table 4 Huge Capital Investments to Limit the Market Growth of Vaccines
Table 5 High Growth Potential in Emerging Countries to Boost the Market for Vaccines
Table 6 Immunization Coverage, By Disease, 2014
Table 7 Inadequate Access to Vaccines A Major Challenge in the Market
Table 8 Regulatory Authorities in Europe
Table 9 Regulatory Authorities in Asia
Table 10 Key Pipeline Vaccines
Table 11 Market Size, By Technology, 2014–2021 (USD Million)
Table 12 Conjugate Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 13 Examples of Inactivated and Subunit Vaccines
Table 14 Inactivated and Subunit Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 15 Live Attenuated Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 16 Toxoid Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 17 Recombinant Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 18 Vaccines Market Size, By Type, 2014–2021 (USD Million)
Table 19 Monovalent Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 20 Examples of Multivalent Vaccines
Table 21 Multivalent Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 22 Market Size, By Disease Indication, 2014–2021 (USD Million)
Table 23 List of Pneumococcal Vaccines
Table 24 Market Size for Pneumococcal Disease, By Region, 2014–2021 (USD Million)
Table 25 List of DTP Vaccines
Table 26 Market Size for DTP, By Region, 2014–2021 (USD Million)
Table 27 List of Influenza Vaccines
Table 28 Market Size for Influenza, By Region, 2014–2021 (USD Million)
Table 29 List of Hpv Vaccines
Table 30 Market for Hpv, By Region, 2014–2021 (USD Million)
Table 31 List of Meningococcal Vaccines
Table 32 Market Size for Meningococcal Disease, By Region, 2014–2021 (USD Million)
Table 33 List of Polio Vaccines
Table 34 Polio Market Size, By Region, 2014–2021 (USD Million)
Table 35 List of Rotavirus Vaccines
Table 36 Market Size for Rotavirus, By Region, 2014–2021 (USD Million)
Table 37 List of Hepatitis Vaccines
Table 38 Market Size for Hepatitis, By Region, 2014–2021 (USD Million)
Table 39 List of MMR Vaccines
Table 40 Market Size for MMR, By Region, 2014–2021 (USD Million)
Table 41 List of Varicella Vaccines
Table 42 Market Size for Varicella, By Region, 2014–2021 (USD Million)
Table 43 List of Other Vaccines
Table 44 Market Size for Other Diseases, By Region, 2014–2021 (USD Million)
Table 45 Market Size, By End User, 2014–2021 (USD Million)
Table 46 Market Size for Pediatrics, By Region, 2014–2021 (USD Million)
Table 47 North America: Market Size for Pediatrics, By Country, 2014–2021 (USD Million)
Table 48 Market Size for Adults, By Region, 2014–2021 (USD Million)
Table 49 North America: Market Size for Adults, By Country, 2014–2021 (USD Million)
Table 50 Market Size, By Region, 2014–2021 (USD Million)
Table 51 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 52 North America: Market Size, By Technology, 2014–2021 (USD Million)
Table 53 North America: Vaccines Market Size, By Type, 2014–2021 (USD Million)
Table 54 North America: Vaccines Market Size, By Disease Indication, 2014–2021 (USD Million)
Table 55 North America: Vaccines Market Size, By End User, 2014–2021 (USD Million)
Table 56 U.S.: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 57 U.S.: Vaccines Market Size, By End User, 2014–2021 (USD Million)
Table 58 Canada: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 59 Canada: Vaccines Market Size, By End User, 2014–2021 (USD Million)
Table 60 Europe: Vaccines Market Size, By Country, 2014–2021 (USD Million)
Table 61 Europe: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 62 Europe: Vaccines Market Size, By Type, 2014–2021 (USD Million)
Table 63 Europe: Vaccines Market Size, By Disease Indication, 2014–2021 (USD Million)
Table 64 Europe: Vaccines Market Size, By End User, 2014–2021 (USD Million)
Table 65 Germany: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 66 U.K.: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 67 France: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 68 Italy: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 69 Spain: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 70 RoE: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 71 Asia: Health Expenditure Per Capita, By Country, 2000 & 2014 (USD)
Table 72 Asia: Vaccines Market Size, By Country, 2014–2021 (USD Million)
Table 73 Asia: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 74 Asia: Vaccines Market Size, By Type, 2014–2021 (USD Million)
Table 75 Asia: Vaccines Market Size, By Disease Indication, 2014–2021 (USD Million)
Table 76 Asia: Vaccines Market Size, By End User, 2014–2021 (USD Million)
Table 77 Japan: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 78 China: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 79 India: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 80 RoA: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 81 RoW: Vaccines Market Size, By Technology, 2014–2021 (USD Million)
Table 82 RoW: Vaccines Market Size, By Type, 2014–2021 (USD Million)
Table 83 RoW: Vaccines Market Size, By Disease Indication, 2014–2021 (USD Million)
Table 84 RoW: Vaccines Market Size, By End User, 2014–2021 (USD Million)
Table 85 Agreements, Collaborations, and Partnerships, 2013-2016
Table 86 Regulatory Approvals, 2013-2016
Table 87 Acquisitions, 2013-2016
Table 88 Expansions, 2013-2016
Table 89 Other Developments, 2013-2016 
 

List of Figures (55 Figures)
 
Figure 1 Vaccines Market Segmentation
Figure 2 Research Design
Figure 3 Top-Down Approach
Figure 4 Bottom-Up Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 Vaccines Market Size, By Technology, 2016 vs 2021 (USD Million)
Figure 8 Global Vaccines Market Size, By Type, 2016 vs 2021 (USD Million)
Figure 9 Global Vaccines Market, By Disease Indication, 2016
Figure 10 Global Vaccines Market Size, By End User, 2016 vs 2021 (USD Million)
Figure 11 Global Vaccines Market, By Region, 2016 (USD Million)
Figure 12 High Prevalence of Diseases and Rising Government & Non-Government Funding for Vaccine Development Primary Growth Drivers for the Global Vaccines Market
Figure 13 Monovalent Vaccines Segment to Witness High Growth During the Forecast Period
Figure 14 Pediatrics Segment to Dominate the Vaccines Market in 2021
Figure 15 Conjugate Vaccines Segment to Account for the Largest Market Share in 2016
Figure 16 U.S. to Dominate the Vaccines Market in 2016
Figure 17 Asia to Witness the Highest Growth Rate in the Vaccines Market During the Forecast Period
Figure 18 Vaccine Market Segmentation
Figure 19 Vaccine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 20 Investors Play an Important Role in the Vaccines Market
Figure 21 Vaccine Funding, By Investor, 2014
Figure 22 Gavi Vaccine Funding, By Type of Investor, 2014
Figure 23 HIV Preventive Vaccines R&D Funding, By Investor, 2014
Figure 24 Regulatory Approval Process for Vaccines
Figure 25 North America Accounted for the Largest Number of Patent Filings in 2012
Figure 26 The U.S. Accounted for Largest Number of Patent Filings Across the Globe (2012)
Figure 27 Conjugate Vaccines Segment to Dominate the Vaccines Market During the Forecast Period
Figure 28 Asian Market for Live Attenuated Vaccines to Register the Highest CAGR During the Forecast Period
Figure 29 North America is Expected to Dominate the Recombinant Vaccines Market During the Forecast Period
Figure 30 Monovalent Vaccines to Dominate the Global Vaccines Market From 2016 to 2021
Figure 31 North America is Expected to Dominate the Multivalent Vaccines Market During the Forecast Period
Figure 32 Pneumococcal Disease Segment Expected to Dominate the Market During the Forecast Period
Figure 33 Asia is Expected to Grow at the Highest CAGR in the Influenza Disease Segment During the Forecast Period
Figure 34 North America to Dominate the Meningococcal Disease Market During the Forecast Period
Figure 35 Asian Market for Hepatitis Vaccines to Grow at the Highest CAGR During the Forecast Period
Figure 36 The Pediatrics End-User Segment Dominates the Global Vaccines Market in 2016
Figure 37 Asia to Witness the Highest Growth Rate in the Vaccines Market for Adults During the Forecast Period
Figure 38 Geographic Snapshot (2016): Emerging Markets to Offer Growth Opportunities
Figure 39 Geographic Benchmarking for Vaccines Technology Market
Figure 40 North America: Vaccines Market Snapshot, 2016
Figure 41 Europe: Vaccines Market Snapshot, 2016
Figure 42 Asia: Vaccines Market Snapshot, 2016
Figure 43 Organic and Inorganic Growth Strategies Adopted By Key Market Players From 2013 to 2016
Figure 44 Global Vaccines Market Share, By Key Player, 2015
Figure 45 Battle for Market Share: Agreements, Collaborations, and Partnerships Were the Preferred Strategies By Market Players
Figure 46 Product Benchmarking for Top 4 Market Players
Figure 47 Pfizer, Inc.: Company Snapshot
Figure 48 Glaxosmithkline, PLC.: Company Snapshot
Figure 49 Merck & Co., Inc.: Company Snapshot
Figure 50 Sanofi Pasteur: Company Snapshot
Figure 51 CSL Limited: Company Snapshot
Figure 52 Emergent Biosolutions: Company Snapshot
Figure 53 Johnson & Johnson: Company Snapshot
Figure 54 Astrazeneca : Company Snapshot
Figure 55 Astellas Pharma Inc.: Company Snapshot

The global vaccines market consists of biological products used to enhance the immune response of a body to prevent protect against diseases such as cholera, typhoid, influenza, hepatitis, and others. These vaccines contain weakened/killed microbes, toxins, or surface proteins for inducing immunity against specific diseases. This market is driven by several factors such as high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. High potential growth in emerging markets and development of therapeutic and adjuvant vaccines have opened an array of opportunities for the market. However, huge capital investments and stringent regulations are hampering the growth of the global market.

The vaccines market is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3%. This market is segmented based on technology, type, disease indication, end-users, and regions.

Based on technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. The conjugate vaccines segment is expected to account for the largest share of the market in 2016. Increasing government support for vaccine development and rising company investments will drive the growth of this market segment.

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. Monovalent vaccines segment is expected to grow at highest rate due to rising prevalence of diseases and increasing government and non-government initiatives for vaccine R&D activities.

On the basis of disease indication, the vaccines market is segmented into pneumococcal disease, influenza, diphtheria, tetanus, and pertussis (DTP), hepatitis, rotavirus, varicella, meningococcal disease, polio, measles, mumps, and rubella (MMR), human papilloma virus (HPV) infection, and others. Pneumococcal disease segment is expected to account for largest share in 2016. This is attributed to the high incidence of pneumococcal infections and increasing initiatives by government organization for immunizations.

Based on end-users, the vaccines market is segmented into paediatrics and adults. The paediatrics segment is expected to account for the largest share of the market in 2016. Increasing prevalence of diseases in children and rising number of awareness programs to promote vaccination will drive the growth of this market.

Vaccine Market

The global vaccines market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to dominate the global market in the forecast period. However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China and India.

The major players in this market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), and Serum Institute of India Pvt. Ltd. (India).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biotechnology Markets on KnowledgeStore
Request Demo